"Loading Stock Price & Valuation Data ..."
Unlock News Summary by Subscribing to iPick.ai Premium!
Ask anything related to QURE. [ FAQ on what and how to ask] For non-QURE questions, click the logo in the upper-right corner to return to the main page and ask there.
CEO:Mr. Matthew Craig Kapusta CPA
Headquarter: Paasheuvelweg 25, Amsterdam, Netherlands, 1105 BP
Industry: Biotechnology, Investment Track: neuroscience-focused, Employees: 221
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
My Watchlist
